AnswersPublished26 sources
Ivonescimab vs Keytruda in PD-L1-Positive NSCLC: The Evidence So Far
In China’s Phase 3 HARMONi 2 trial, ivonescimab more than doubled median progression free survival versus pembrolizumab (11.14 vs 5.82 months; HR 0.51), and Akeso later reported a statistically significant interim ove... HARMONi 6 provides additional survival evidence in Chinese squamous NSCLC, but it compared ivone...
Published byEdited with GPT-5.6 TerraImages generated with GPT Image 2
Research answer
Key takeaways
- In China’s Phase 3 HARMONi 2 trial, ivonescimab more than doubled median progression free survival versus pembrolizumab (11.14 vs 5.82 months; HR 0.51), and Akeso later reported a statistically significant interim ove...
- HARMONi 6 provides additional survival evidence in Chinese squamous NSCLC, but it compared ivonescimab plus chemotherapy with tislelizumab plus chemotherapy—not Keytruda.
- The key Western tests are further global trial readouts, including HARMONi 3 and HARMONi 7, plus the FDA’s review of a separate EGFR mutated NSCLC indication.
AI Prompt
openai.comCreate a landscape editorial hero image for this Studio Global article: How has Akeso and Summit Therapeutics’ first-in-class PD-1/VEGF bispecific antibody ivonescimab performed versus pembrolizumab (Keytruda) in. Article summary: Ivonescimab has produced the strongest head-to-head result yet reported against pembrolizumab in a China-only first-line PD-L1-positive NSCLC trial: a large PFS advantage and, now, a statistically significant interim OS . Topic tags: general, government, news, general web, user generated. Style: premium digital editorial illustration, source-backed research mood, clean composition, high detail, modern web publication hero. Use reference image context only for broad subject, composition, and topical grounding; do not copy the exact image. Avoid: logos, brand marks, copyrighted characters, real person likenesses, fake screenshots, UI text, readable text, watermar
Ivonescimab is one of the most closely watched attempts to improve on PD-1 immunotherapy in lung cancer. Its central evidence is a direct Phase 3 comparison with pembrolizumab (Keytruda) in China, where it delivered a substantial progression-free-survival advantage and has since been reported to meet a key interim overall-survival endpoint. That is an important signal, but it is not yet a definitive answer for patients or clinicians in the U.S. and Europe.
The direct HARMONi-2 comparison with pembrolizumab
HARMONi-2 enrolled previously untreated patients in China with PD-L1-positive, locally advanced or metastatic non-small cell lung cancer (NSCLC). It compared ivonescimab monotherapy with pembrolizumab monotherapy.
At the primary analysis, median progression-free survival (PFS)—the time before disease progression or death—was 11.14 months with ivonescimab versus 5.82 months with pembrolizumab. The hazard ratio was 0.51 (95% CI 0.38–0.69; p<0.0001), meaning the study found a 49% lower risk of progression or death in the ivonescimab arm at that analysis. 1
14
In September 2026, Akeso reported that a prespecified interim analysis of overall survival (OS) met the trial’s key secondary endpoint, with a statistically significant and clinically meaningful advantage over pembrolizumab, as assessed by the independent data monitoring committee. 3
7
The limitation is crucial: the companies had not publicly disclosed the mature numerical OS results in the material provided—such as median OS, hazard ratio, confidence interval, or detailed subgroup outcomes. Until those data are presented and independently scrutinized, the size and consistency of the survival advantage cannot be fully assessed.
Why the result matters
Ivonescimab is a bispecific antibody designed to combine PD-1 blockade with VEGF inhibition in one molecule. Summit obtained rights to develop and commercialize the drug in the U.S., Canada, Europe, and Japan, while Akeso retained rights in other territories, including China. 46
56
The HARMONi-2 result matters because it is a head-to-head randomized Phase 3 test against pembrolizumab monotherapy, rather than an indirect cross-trial comparison. The PFS difference is large enough to make ivonescimab a serious potential challenger to PD-1-based treatment in the specific trial setting.
But it should not be interpreted as proof that ivonescimab is superior to every current first-line regimen. HARMONi-2 was conducted only in China and tested monotherapy against monotherapy. Treatment choices elsewhere often depend on PD-L1 level, histology, molecular profile, symptoms, comorbidities, and whether chemotherapy is used alongside immunotherapy.
Chinese approval and HARMONi-6 survival data
Ivonescimab plus chemotherapy received approval from China’s National Medical Products Administration for first-line advanced squamous NSCLC in August 2026. 19
That approval followed HARMONi-6, a Phase 3 study in previously untreated advanced squamous NSCLC. At a prespecified interim OS analysis, ivonescimab plus chemotherapy produced median OS of 27.9 months, compared with 23.7 months for tislelizumab plus chemotherapy. The hazard ratio for death was 0.66 (95% CI 0.50–0.87; one-sided p=0.0017). 17
18
HARMONi-6 strengthens the broader clinical case that the PD-1/VEGF approach can produce survival benefit in a Chinese NSCLC population. Still, it does not replicate the HARMONi-2 comparison: it used chemotherapy in both arms, enrolled squamous NSCLC, and used tislelizumab rather than pembrolizumab as the comparator.
There is also a reason to focus on mature datasets rather than early top-line results. Reporting on the Chinese label indicated that the updated HARMONi-6 PFS estimate was less pronounced than the earlier disclosed estimate: median PFS was reported as 12.48 versus 8.31 months, HR 0.72, compared with an earlier 11.1 versus 6.9 months, HR 0.60. 20 That does not negate the reported OS finding, but it underscores why complete follow-up, protocols, and peer-reviewed reporting matter.
What remains uncertain in Western markets
Generalizability beyond a China-only trial
The most important question is whether HARMONi-2’s PFS and reported OS advantage can be reproduced in a multiregional population, including Western patients. Differences in patient populations, clinical practice, subsequent treatments, and treatment standards can affect how readily a single-country result transfers to another setting.
The lack of disclosed numerical OS data also limits interpretation. A finding that an interim endpoint was statistically significant is meaningful, but clinicians and regulators need the effect size, confidence interval, duration of follow-up, safety data, and subgroup analyses to judge clinical relevance.
HARMONi-3’s interim PFS miss
The global HARMONi-3 program is particularly important because it is designed to test ivonescimab plus chemotherapy in first-line metastatic NSCLC. Its first interim PFS analysis did not meet statistical significance, though the study remained blinded and ongoing; Summit was reported to be guiding to a final PFS readout in the second half of 2026 alongside interim OS analyses. 20
This means HARMONi-3 cannot yet be considered confirmatory evidence of a Western benefit. Encouraging subgroup or interim survival observations, if any, are hypothesis-generating until the prespecified primary analyses mature.
HARMONi-7 is the cleaner global test of the monotherapy thesis
Summit lists HARMONi-7 as a multiregional Phase 3 monotherapy study in first-line metastatic NSCLC with high PD-L1 expression. 30
36 Its relevance is straightforward: a robust international trial in a population suited to immunotherapy monotherapy could help determine whether the HARMONi-2 finding is reproducible beyond China.
The nearer FDA decision is in a different NSCLC population
Summit’s U.S. biologics license application is not for first-line PD-L1-positive disease or for the HARMONi-2 monotherapy regimen. It seeks approval of ivonescimab plus platinum-doublet chemotherapy for previously treated, EGFR-mutated, locally advanced or metastatic non-squamous NSCLC after a third-generation EGFR tyrosine kinase inhibitor. The FDA’s stated goal action date is November 14, 2026. 30
41
In the global HARMONi trial supporting that application, ivonescimab plus chemotherapy significantly improved PFS: median PFS was 6.8 months versus 4.4 months with placebo plus chemotherapy, with an HR of 0.52. However, the primary OS analysis was not statistically significant. 6
34 A later company-reported analysis gave an OS HR of 0.76 in both the overall intention-to-treat population and the Western-patient subgroup, but this does not change the fact that the primary OS analysis was not statistically significant.
21
That distinction matters for both regulatory and commercial expectations: even an approval in the EGFR-mutated, post-TKI setting would not establish ivonescimab as a first-line replacement for pembrolizumab in PD-L1-positive NSCLC.
Bottom line
Ivonescimab has delivered a striking PFS win over pembrolizumab in the China-based HARMONi-2 trial—11.14 versus 5.82 months—and Akeso has reported that interim OS also crossed its prespecified threshold. 1
3 HARMONi-6 adds a separate, peer-reviewed interim survival result in Chinese squamous NSCLC.
17
The evidence is promising, not final. The decisive next steps are public disclosure of the full HARMONi-2 OS dataset, mature global HARMONi-3 results, progress from HARMONi-7, and the FDA’s assessment of the separate EGFR-mutated NSCLC application. Until then, ivonescimab is best viewed as a strong China-based clinical signal with meaningful—but unproven—potential to reshape treatment in Western markets.
This article summarizes trial and regulatory information and is not medical advice. Treatment decisions should be made with an oncology team.
Studio Global AI
Continue your research
This page includes a source-backed answer you can continue inside Studio Global.
People also ask
What is the short answer to "Ivonescimab vs Keytruda in PD-L1-Positive NSCLC: The Evidence So Far"?
In China’s Phase 3 HARMONi 2 trial, ivonescimab more than doubled median progression free survival versus pembrolizumab (11.14 vs 5.82 months; HR 0.51), and Akeso later reported a statistically significant interim ove...
What are the key points to validate first?
In China’s Phase 3 HARMONi 2 trial, ivonescimab more than doubled median progression free survival versus pembrolizumab (11.14 vs 5.82 months; HR 0.51), and Akeso later reported a statistically significant interim ove... HARMONi 6 provides additional survival evidence in Chinese squamous NSCLC, but it compared ivonescimab plus chemotherapy with tislelizumab plus chemotherapy—not Keytruda.
What should I do next in practice?
The key Western tests are further global trial readouts, including HARMONi 3 and HARMONi 7, plus the FDA’s review of a separate EGFR mutated NSCLC indication.